You have read all your free articles, to continue reading subscribe to read the rest of this content.
InDex Pharmaceuticals Holding has received positive responses from FDA and EMA regarding its phase III development of the TLR9 agonist cobitolimod, for the treatment of moderate to severe ulcerative colitis. Following the phase IIb study CONDUCT meeting its primary endpoint in August 2019, dialogAlready a subscriber Login You have read…
Nordic Biomarker is partnering with private equity company Procuritas. ”Together with our new Swedish majority owner Procuritas, who share our vision for the company to become a leading global supplier of products for reliable coagulation diagnostics, we are now in a better position than ever bAlready a subscriber Login You…
Oncopeptides has announced that the Oncologic Drugs Advisory Committee (ODAC), of the FDA, has finalized the discussion on the benefit-risk profile of Pepaxto. A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient populatioAlready a subscriber Login You have read…
Oasmia Pharmaceutical is launching its product, Apealea 60 mg, an ovarian cancer treatment drug, in Sweden, Denmark and Finland. The first batch of the drug has been shipped to distributors in these countries, states the company. Transition towards becoming a fully integrated pharmaceutical compAlready a subscriber Login You have read…
